## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($146.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Neurocrine Biosciences fails mid-stage study of depression drug**
- Source: MSN | 20251204T042204 | Neutral | Relevance: 99%
- Neurocrine Biosciences' mid-stage study for its depression drug failed to meet its primary endpoint. This setback signals a potential halt in the development of this particular candidate for major depressive disorder.

**2. TD Cowen Maintains Neurocrine Biosciences (NBIX) Buy Recommendation**
- Source: Nasdaq | 20251205T190400 | Bullish | Relevance: 98%
-  TD Cowen has reaffirmed its "Buy" recommendation for Neurocrine Biosciences (NBIX). Analysts project a 15.00% upside, with an average one-year price target of $177.35/share. Funds and institutions show slight increases in ownership, despite a minor decrease in total institutional shares over the last quarter.

**3. Neurocrine Biosciences (NBIX) Is Up 5.1% After Peer-Reviewed Study Highlights INGREZZAâ€™s Clinical Profile**
- Source: Sahm | 20251203T042204 | Somewhat-Bullish | Relevance: 97%
- Neurocrine Biosciences saw a 5.1% increase after a peer-reviewed study reinforced the clinical profile of its FDA-approved drug, INGREZZA, for tardive dyskinesia. The review consolidates over a decade of research, highlighting INGREZZA's distinct pharmacologic and dosing characteristics compared to other treatments. This positive development could strengthen INGREZZA's market position, though the company still faces challenges related to payer access and reimbursement.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |
| 2025-12-05 | TD Cowen | $200 | $175 | +14% |
| 2025-11-11 | Morgan Stanley | $173 | $178 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | RBC Capital | main | Outperform |
| 2025-12-05 | TD Cowen | main | Buy |
| 2025-11-11 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.72M) |
| Sells | 5 ($2.33M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 17.0x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (2 raises, avg +13%). Insider selling cluster ($2.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.5B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 17.0 |
| Current P/E | 22.6 |
| YoY Growth | 32.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 2.3% (minimal 5-day change). Below STRENGTH zone by 0.7pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Outperforming sector by 4.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.10), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.34% (CS: 76) | Neutral |
| RSI_14 | 65.5 | Neutral |
| MACD Histogram | 1.10 | Bullish |
| vs SMA20 | 1.058x | Above |
| vs SMA50 | 1.083x | Above |
| vs SMA200 | 1.215x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $155.51
- **Stop Loss:** $146.61 (5.7% risk)
- **Target:** $164.41 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $8,708.56
- **Portfolio %:** 8.71%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*